Liraglutide vs Semaglutide in the Philippines: The Older GLP-1 vs the New Standard

Before branded semaglutide became the most-recognised name in GLP-1 weight loss in the Philippines, branded liraglutide was the established choice. branded liraglutide is the manufacturer's branded liraglutide, an older GLP-1 receptor agonist requiring daily injection. It was FDA Philippines registered for chronic weight management years before branded semaglutide rose to prominence, and Filipino weight-management clinics still carry significant branded liraglutide prescriptions among long-term patients who started before semaglutide arrived.

This guide is a focused branded liraglutide versus branded semaglutide comparison for Filipino patients in 2026. We cover the molecular and pharmacological differences, the dosing-schedule convenience question, weight-loss outcomes from published trials, current Philippine pricing, and the authentication considerations for both brands.

For the broader branded semaglutide context, see our branded semaglutide Philippines complete guide. For the head-to-head with tirzepatide, see branded tirzepatide vs branded semaglutide for weight loss. For the broader pillar on tirzepatide as the next step beyond semaglutide, see Tirzepatide Philippines complete guide.

The two molecules

Both molecules act through the same GLP-1 receptor mechanism. The structural differences (liraglutide is a 31-amino-acid peptide; semaglutide is a 31-amino-acid peptide with different fatty-acid attachment) produce the half-life difference that drives dosing frequency.

Weight-loss outcomes from trials

branded liraglutide (liraglutide 3 mg) in SCALE-Obesity (NEJM 2015):

• 3,731 adults with obesity randomised to placebo or liraglutide 3 mg daily.
• Mean body weight reduction at 56 weeks: 8.0% on drug versus 2.6% on placebo.
• Total liraglutide weight reduction: ~5.4% beyond placebo.

branded semaglutide (semaglutide 1 mg) in SUSTAIN-1:

• Type 2 diabetes patients; weight-loss endpoint secondary.
• Approximately 4 to 6% weight reduction at 30 weeks.

high-dose branded semaglutide (semaglutide 2.4 mg) in STEP-1:

• 1,961 adults with overweight or obesity.
• Mean body weight reduction at 68 weeks: 14.9% on drug versus 2.4% on placebo.

The comparison: at maximum approved dose, semaglutide produces roughly twice the weight loss of liraglutide. The mechanism is the same; the longer-acting molecule plus the higher effective dose explain the magnitude difference.

For Filipino patients comparing branded liraglutide 3 mg daily to branded semaglutide 1 mg weekly, the expected weight-loss difference is meaningful: approximately 5 to 8% on branded liraglutide versus approximately 8 to 12% on branded semaglutide at typical doses.

Dosing schedule: daily vs weekly

This is often the deciding factor for Filipino patients.

branded liraglutide dosing schedule:

• Start at 0.6 mg daily for 1 week.
• Increase to 1.2 mg daily for 1 week.
• Increase to 1.8 mg daily for 1 week.
• Increase to 2.4 mg daily for 1 week.
• Maintain at 3.0 mg daily.
• Total titration: 5 weeks to maximum dose.

branded semaglutide dosing schedule:

• Start at 0.25 mg weekly for 4 weeks.
• Increase to 0.5 mg weekly for 4 weeks.
• Increase to 1 mg weekly for 4 weeks.
• Optional increase to 2 mg weekly.
• Total titration: 12 to 16 weeks to top doses.

Practical implications:

• Daily injection burden: branded liraglutide requires 365 injections per year. branded semaglutide requires 52. The cumulative time, supply needs (pen needles, alcohol wipes), and technical attention favour branded semaglutide.
• Adherence: studies on chronic medications consistently show better adherence with weekly versus daily dosing. Filipino TRT and weight-management clinics report similar patterns.
• Side-effect adaptation: daily dosing produces stable plasma concentrations sooner. Weekly dosing produces peak-trough variation that can drive cycle-of-week side-effect patterns.
• Missed doses: a missed branded liraglutide dose has minimal impact (next-day dose continues). A missed branded semaglutide dose can be made up within a few days but missing more requires careful retitration.

For most Filipino patients, the once-weekly schedule of branded semaglutide is meaningfully more convenient. This drives most current prescription preference toward branded semaglutide over branded liraglutide for new patients.

Philippine pricing in 2026

branded liraglutide pricing reflects multiple pens for the daily-dosing schedule. Each the branded liraglutide pen lasts approximately 1 week at maximum dose; a typical 5-pen pack covers approximately 5 weeks.

Per-month cost comparison:

• branded liraglutide at 3 mg daily: approximately PHP 28,000 to 38,000 per month.
• branded semaglutide at 1 mg weekly: approximately PHP 14,000 to 18,000 per month.

branded semaglutide is meaningfully more cost-efficient at typical doses, while producing larger weight-loss effects. The economic case for branded semaglutide over branded liraglutide is strong for new Filipino patients.

Side-effect profiles

Both medications produce similar side-effect categories because the GLP-1 receptor mechanism is shared. Common:

• Nausea, especially during titration.
• Diarrhoea or constipation.
• Vomiting (less common, dose-related).
• Fatigue.
• Reduced appetite.
• Injection-site reactions.

branded liraglutide-specific patterns:

• Daily titration produces faster side-effect adaptation than weekly titration.
• Daily injection means daily injection-site management, with more frequent site rotation needed.

branded semaglutide-specific patterns:

• Side effects can cluster in the days after weekly injection, then resolve before the next dose.
• Less daily injection burden but bigger peak-side-effect days.

Both share the GLP-1 class warnings: pancreatitis, gallbladder disease with rapid weight loss, and the thyroid C-cell concern.

Why Filipino patients still use branded liraglutide

Despite the cost and convenience advantages of branded semaglutide, some Filipino patients remain on branded liraglutide. Reasons:

1. Started before branded semaglutide was widely available. Long-term branded liraglutide patients with stable response often stay rather than switching.
2. On-label weight-management indication. branded liraglutide is FDA Philippines approved specifically for chronic weight management. branded semaglutide is approved for type 2 diabetes; weight-loss use is off-label.
3. Insurance and coverage. Where Filipino health insurance covers GLP-1 medication, the on-label indication matters for reimbursement.
4. Daily dosing preference. A small subset of patients prefer daily injection because they find weekly dosing creates anxiety about side effect timing or because they prefer the smaller daily dose-size.
5. Avoiding semaglutide-specific concerns. Some patients have heard about branded semaglutide-specific side effects (branded semaglutide face, severe gastric stasis cases) and prefer the longer-established liraglutide history.

For patients on stable branded liraglutide with good response, switching is not necessarily indicated. For new patients starting GLP-1 weight-loss therapy, branded semaglutide or high-dose branded semaglutide at appropriate doses generally has the better cost-benefit profile.

Authentication for both brands

Both branded liraglutide and branded semaglutide are the manufacturer products with similar authentication frameworks:

• Holographic seal on the carton.
• Lot number printed on three locations.
• Specific colour-coding by dose strength.
• Country of manufacture printed on the carton.
• PI leaflet included.

Counterfeit branded liraglutide exists in Southeast Asia but is less common than counterfeit branded semaglutide, partly because branded liraglutide's market share is smaller. The authentication patterns are similar across both brands.

For the visual authentication checklist, see how to spot fake tirzepatide and branded semaglutide.

Lab verification

Lumen Labs runs analytical pathway for both brands:

• HPLC purity at the relevant absorbance wavelength.
• LC-MS identity: liraglutide 3751.2 Da, semaglutide 4113.6 Da. The masses are distinct, allowing clear differentiation.
• Quantitation against label dose.
• Optional endotoxin and microbial limits.

The output is a certificate of analysis confirming whether the submitted pen contains the labelled molecule at the labelled concentration.

Bottom line on branded liraglutide versus branded semaglutide for Filipinos

For new Filipino patients starting GLP-1 weight-loss therapy in 2026, branded semaglutide generally has the better cost-convenience-effect profile. Once-weekly dosing is more convenient than daily, monthly cost is roughly half, and weight-loss effect is larger.

Patients on stable branded liraglutide with good response, on-label indication preference, or other specific reasons may reasonably continue. Switching from branded liraglutide to branded semaglutide is straightforward and Filipino weight-management clinics handle the transition routinely.

For both brands, registered registered Philippine pharmacy chains supply has very low counterfeit risk. Anything else benefits from analytical verification before injection.

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. branded liraglutide and branded semaglutide are prescription medications; consult a qualified Philippine licensed physician before starting, adjusting, or stopping any therapy.